ANTENGENE-B: (1) PROPOSALS FOR GENERAL MANDATES TO ISSUE AND RESELL SHARES AND TO REPURCHASE SHARES; (2) RE-ELECTION OF DIRECTORS; (3) PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION AND THE ADOPTION OF THE EIGHTH AMENDED AND RESTATED MEMORANDUM AND A
ANTENGENE-B: FORM OF PROXY FOR THE ANNUAL GENERAL MEETING
ANTENGENE-B: NOTICE OF THE ANNUAL GENERAL MEETING
ANTENGENE-B: Notification Letter to Registered Shareholders and Reply Form
ANTENGENE-B: Notification Letter to Non-registered Holders and Reply Form
ANTENGENE-B: 2023 ANNUAL REPORT
ANTENGENE-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
ANTENGENE-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023 AND PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF THE NEW MEMORANDUM AND ARTICLES OF ASSOCIATION AND CHANGE IN USE OF PROCEEDS
ANTENGENE-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023 AND PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF THE NEW MEMORANDUM AND ARTICLES OF ASSOCIATION AND CHANGE IN USE OF PROCEEDS
ANTENGENE-B: NOTICE OF DATE OF BOARD MEETING
ANTENGENE-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
ANTENGENE-B: Notification Letter and Reply Form to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
ANTENGENE-B: Notification Letter and Reply Form to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
ANTENGENE-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
ANTENGENE-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
ANTENGENE-B: VOLUNTARY ANNOUNCEMENT SELINEXOR (XPOVIO), ANTENGENE''S FIRST-IN-CLASS NEW DRUG, SUCCESSFULLY INCLUDED IN 2023 NATIONAL REIMBURSEMENT DRUG LIST
ANTENGENE-B: VOLUNTARY ANNOUNCEMENT APPROVAL OF NDA BY THE PHARMACEUTICAL ADMINISTRATION BUREAU OF MACAU FOR ATG-010 (SELINEXOR) FOR THE TREATMENT OF RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
ANTENGENE-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
ANTENGENE-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023
ANTENGENE-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2023
No Data